Iksuda Therapeutics closes $47 million financing round
Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, has completed a US$47 million financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform […]
